Free Trial
→ Here’s How to Claim Your Stake in Elon’s Private Company, xAI (From Brownstone Research) (Ad)
NASDAQ:SMTI

Sanara MedTech Q1 2025 Earnings Report

Sanara MedTech logo
$33.06 +0.83 (+2.56%)
As of 02:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Sanara MedTech EPS Results

Actual EPS
N/A
Consensus EPS
-$0.31
Beat/Miss
N/A
One Year Ago EPS
N/A

Sanara MedTech Revenue Results

Actual Revenue
N/A
Expected Revenue
$23.48 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sanara MedTech Announcement Details

Quarter
Q1 2025
Date
5/14/2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Sanara MedTech Earnings Headlines

Sanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025
April 23, 2025 | globenewswire.com
Sanara MedTech to Present at Investor Showcase
April 22, 2025 | tipranks.com
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
May 2, 2025 | Brownstone Research (Ad)
Sanara MedTech to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
April 10, 2025 | globenewswire.com
Where Sanara MedTech Stands With Analysts
March 28, 2025 | benzinga.com
Earnings call transcript: Sanara Medtech Q4 2024 shows strong growth
March 27, 2025 | uk.investing.com
See More Sanara MedTech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sanara MedTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sanara MedTech and other key companies, straight to your email.

About Sanara MedTech

Sanara MedTech (NASDAQ:SMTI), a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

View Sanara MedTech Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles